HIV

The Pharmacy Times® human immunodeficiency virus (HIV) resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
[[thumbnail_alt_text]]
Although antiretroviral therapy is an important option for patients with HIV, the viral reservoir has been a major obstacle for researchers looking to effectively cure the disease.
 
[[thumbnail_alt_text]]
According to results from a recent study, a functional cure for HIV may lie in identifying the viral reservoirs in which HIV places copies of its viral genetic material into cell genomes.
[[thumbnail_alt_text]]
According to the study authors, with a higher antigen valency, antibodies have more sites to latch onto; however, including a higher antigen valency in a vaccine does not mean it will work better.
[[thumbnail_alt_text]]
Antiretroviral therapy’s limitations lead to new efforts to treat the virus by neutralizing antibodies.
[[thumbnail_alt_text]]
Despite, antiretroviral therapy, HIV can hide in blood and tissue. 
[[thumbnail_alt_text]]
Fingolimod (Gilenya), which is approved by the FDA to treat multiple sclerosis flare-ups, may also block HIV and reduce the latent reservoir.
[[thumbnail_alt_text]]
A new study found that it’s safe for patients with HIV to receive HIV-positive kidneys. 
[[thumbnail_alt_text]]
As patients return to their routines of returning to pharmacies and the inevitable discussions about COVID-19 begin, it may be a good time to discuss the range of tests that the CDC recommends.
[[thumbnail_alt_text]]
Globally, dolutegravir is expected to be a part of treatment for approximately 15 million people living with HIV by 2021.
[[thumbnail_alt_text]]
Significant morbidity and mortality are associated with an aging population due to cardiovascular disease, which is very common in HIV-infected persons.
[[thumbnail_alt_text]]
Fostemsavir is indicated for adults with drug resistant HIV.
[[thumbnail_alt_text]]
Dolutegravir tablets are intended to treat pediatric patients at least 4 weeks old and at least 6 pounds who have never been treated for HIV or who have been treated, but not with an integrase strand transferase inhibitor class drug, according to the press release.